康莱特注射液对高龄非小细胞肺癌化疗患者生存质量的影响

Effect of Kanglaite injection on quality of life of senile patients with non-small cell lung cancer treated with chemotherapy

将 68例高龄 (≥ 70岁 )非小细胞肺癌 (non smallcelllungcancer ,NSCLC)患者随机分为康莱特注射液加化疗(治疗组 3 4例 )与单纯化疗 (对照组 3 4例 )两组。治疗组采用以NVB +DDP/CBP(或Taxol +DDP/CBP ,Vp 16+DDP/CBP ,VM 2 6+DDP/CBP ,MMC +VDS +DDP)方案化疗 ,同时应用康莱特注射液 2 0 0mL/d静脉滴入 ,连用 2 0d ;对照组单纯应用相同方案化疗。至少完成 2个周期 ,每周期化疗前后进行疗效对比评价。结果治疗组与对照组比较 ,Karnofsky(KPS)评分改善者分别为 40、13例次 ,两组KPS评分分布上的变化差异有统计学意义 ,χ2 =2 7 14 ,P <0 0 0 1;体重增加者分别为 2 8、8例 ,两组体重变化分布上差异有统计学意义 ,χ2 =3 4 0 5 ,P <0 0 0 1;胸痛、血痰、乏力、食欲不振明显改善比率分别为 79 4%与 5 5 9%、76 5 %与 46 1%、5 2 9%与 8 8%、47 1%与 11 8% ,两组差异均有统计学意义 ,P <0 0 5。

Sixty eight senile patients ≥70 years with non small cell lung cancer (NSCLC) and were randomly divided into two groups: control group (34 cases) and treatment group (34 cases),and those were comparable. The patients in control group received chemotherapy alone, while the patients in treatment group received chemotherapy combined with Kanglaite injection.The chemotherapy scheme administrated was NVB+DDP/CBP(Taxol+ DDP/CBP, Vp 16+DDP/CBP,VM26+DDP/CBP,MMC+VDS+DDP).The number of Karnofsky score improvement in treatment group and control group was 40 vs 13 and there was a significant difference in distribution between the two groups, χ 2=27 14, P <0 001 .The number of body weight gain was 28 vs 8 and there was a significant difference in distribution between the two groups, χ 2=34 05, P <0 001.The rates of symptom relief in chest pain, bloody sputum, fatigue, anepithymia between treatment group and control group were 79 4 % vs 55 9 %,76 5 % vs 46 1 %,52 9 % vs 8 8 %,47 1 % vs 11 8 % and there were significant differences between these in the two groups, P <0 05.